Lightstone Ventures

Lightstone Ventures has closed its third fund at $375 million.

Lightstone Ventures is seeking to raise $350 million for its third fund, according to an SEC filing.

Cambridge, Massachusetts-based Cyteir Therapeutics, a developer of synthetic lethal therapies that treat cancer and autoimmune disease, has raised $29 million in Series B financing. Venrock led the round with participation from other investors that included Celgene, Lightstone Ventures and DROIA Oncology Ventures.

Cambridge, Massachusetts-based Gemini Therapeutics, a new precision medicine company , has closed $42.5 million in Series A financing. Atlas Venture, Lightstone Ventures and OrbiMed led the round.

The Dementia Discovery Fund, which is managed by SV Life Sciences, has invested $5 million in the initial financing round of Cerevance. Cerevance, a drug discovery company with offices in Boston and Cambridge, U.K., has raised $36 million in commitments of equity and non-dilutive capital from Lightstone Ventures and Takeda Pharmaceuticals Co Ltd.

Newly launched neuroscience company Cerevance has raised $36 million in funding. The company's investors are Takeda Pharmaceutical Company Limited and Lightstone Ventures.

Foundry Innovation & Research 1 Ltd (Fire 1) said April 12 that it closed its Series B financing at $7.5 Existing investors including Lightstone Ventures and New Enterprise Associates, as well as Medtronic, participated in the round. Foundry also named Conor Hanley as its President and CEO. Dublin-based FIRE1 is a medical device company.

Tizona Therapeutics Inc, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, raised $43 million in Series B funding. Abingworth and Canaan Partners led the round with participation from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners.

Locanabio Inc, an RNA-targeting gene therapy company, has raised $100 million in Series B financing.

Burlingame, California-based Tallac Therapeutics Inc, a biopharmaceutical company focused on fighting cancer, has raised $62 million in Series A financing.

Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing.

Gilead Sciences Inc has agreed to invest $300 million in Tizona Therapeutics, a clinical-stage immunotherapy company.

Burlingame, California-based ALX Oncology Holdings Inc, a immuno-oncology company, has raised $161.5 million for its IPO after pricing its 8.5 million shares at $19 per share.

Cerevance, a private drug discovery and development company focused on brain diseases, has raised $45 million in Series B financing.

Roche has closed its previously announced acquisition of Lexington, Massachusetts-based Promedior, a biotech company.

Roche has agreed to acquire Lexington, Massachusetts-based Promedior, a biotech company. According to terms of the agreement, Roche will make an upfront cash payment of $390 million. Promedior's backers include Morgenthaler Ventures, HealthCare Ventures, Forbion, Easton Capital, Fibrotec Ventures and Polaris Partners.